|
Synonyms: ABBV-101 | Compound 1 [US20240109877]
Compound class:
Synthetic organic
Comment: Omtebrutideg is the INN for a Bruton tyrosine kinase PROTAC degrader. It is proposed for antineoplastic effects. The structure indicates that it is designed to engage the cereblon (CRBN) E3 ubiquitin ligase. Available evidence suggests that omtebrutideg is likely the INN for Abbvie's lead BTK PROTAC ABBV-101 [2-3]. Targeted protein degradation is intended as a strategy to overcome BTK inhibitor resistance in B cell malignancies.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bian Z, Burke JP, Jia ZJ, Jiang X, Katcher MH, Mali VR, Marin VL, Noey EL, Okano A, Rivkin AA et al.. (2024)
Pyrimidines for degrading bruton's tyrosine kinase. Patent number: US20240109877A1. Assignee: AbbVie Inc. Priority date: 21/03/2023. Publication date: 04/04/2024. |
|
2. Pan C, Gururaja TL, Li H, Nguyen H, Zhai Y, Zhai X, Ding RX, Mathew R, Hoh HY, JiaZJ et al.. (2023)
Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies. Blood, 142 (Supplement 1): 1887. DOI: 10.1182/blood-2023-184835 |
|
3. Sabakhtarishvili G, Alshebli M, Bajwa O, Tabbara IA. (2025)
Bruton Tyrosine Kinase Degraders: Current Concepts. Am J Clin Oncol, 48 (5): 257-261. [PMID:39950399] |